# Retatrutide trial results: Phase 2 and all reported Phase 3 readouts

> Complete numeric summary of retatrutide clinical trials: Phase 2 in NEJM 2023 and the Phase 3 TRIUMPH and TRANSCEND-T2D programmes.

Canonical: https://yezz.co.uk/trial-results · Last reviewed: 2026-09-11 · Author: Nick Johnson, Independent Prescription Pricing Analyst, Medstack Ltd

## Key facts
- TRIUMPH-1 (pivotal): −28.3% average body weight at 80 weeks on 12 mg; 45.3% lost ≥30%; the 104-week extension reached −30.3% in participants with BMI ≥35.
- TRIUMPH-2 (with type 2 diabetes): −20.8% at 80 weeks, HbA1c down ~1.6%. TRIUMPH-3 (severe obesity with cardiovascular disease): −22.6%.
- TRIUMPH-4 (knee osteoarthritis): −28.7% at 68 weeks. TRANSCEND-T2D-1: HbA1c −2.0%, weight −16.8% at 40 weeks.
- TRIUMPH-5 — the head-to-head against tirzepatide (Mounjaro) — reports late 2026/2027; until then cross-trial comparisons are extrapolations, not findings.
- All figures are trial averages with intensive clinical support — not promises of individual results.

---
Yezz is an independent UK information site run by Medstack Ltd. It sells nothing and provides general information, not medical advice.
Cite as: Nick Johnson. "Retatrutide trial results: Phase 2 and all reported Phase 3 readouts". Yezz, 2026-09-11. https://yezz.co.uk/trial-results